EN DE
Watch Sipai Health Technology Co. Ltd. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sipai Health Technology Co. Ltd. (0314) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Sipai Health Technology Co. Ltd. stock HK$0.43, price HK$1.64, that is 73.5% below the price, quality 41 out of 100. Rating: strongly overvalued. Calculated from audited financials with 6 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

SH Sipai Health Technology Co. Ltd. logo Thin data Nov 14, 2026

Sipai Health Technology Co. Ltd.

0314 · HK

Far too expensive (fair value 74% below the price), weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Generates free cash flow 
Quality 41/100 
Revenue last quarter 40% below a year ago. 
Dilution deducted on Oct 29: HK$0.5100 → HK$0.4335 
Fair value HK$0.4335 · Strongly overvalued 
Falling price (downtrend) 
Weak Growth (revenue 5y −5.7 %/yr in CNY) 
Loss-making · -0.6% net margin (TTM) 
Trails peers (1/10) 
Narrow moat 12/100 · thin data
Thin data 
⚠ Dilution
Watch Sipai Health Technology Co. Ltd. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$42.10 HK$1.18 Fair Value HK$0.4335 Dec 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

47‑month range HK$1.18 – HK$42.10 · fair‑value band HK$0.4335 – HK$0.4420 · the HK$1.64 price screens above the HK$0.4335 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.

Follow Sipai Health Technology Co. in your weekly email

Every Wednesday you see whether Sipai Health Technology Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People's Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business.

Show moreShow less

The Specialty Pharmacy Business segment provides specialty pharmacies and value-added professional pharmacist services; focuses on innovative medicines for the treatment of oncology; pharmaceutical supply chain network for health insurance services; and other critical illnesses.

The Physician Research Assistance Business segment offers pharmaceutical companies and other clinical trial institutions site management organization services, including site feasibility, site initiation, patient recruitment, patient management, data entry and document management, on-site drug management and bio-sample management, site closure, and others; and services for image management in clinical trials.

The Health Insurance Services Business segment provides insurance brokerage services to insurance companies; and health management services to insurance carriers and enterprise clients. The company was founded in 2014 and is headquartered in Putuo, the People's Republic of China.

Stock analysis

Sipai Health Technology Co. Ltd. (0314) currently trades at HK$1.64, while our model-based Fair Value estimate is HK$0.4335, 74% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of HK$0.9700 per share, and 0 of the 6 models we run sit above the HK$1.64 price.

Bear case: the Multiples group reads lowest at HK$0.4600, and 6 of the 6 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$0.4335 (bear) to HK$0.4420 (bull), the price of HK$1.64 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Sipai Health Technology Co. Ltd. reported revenue of 2.0B CNY in FY2025 versus 3.5B CNY in FY2021, a compound −12.7%/yr. Reported net income was −121M CNY in FY2025.

Key figures

Market cap HK$1.2B (≈ $152M) Micro · P/S ratio 0.62 · Net margin −0.6% · Return on equity −0.3% · Return on assets (EBIT) −15.2% (5-year average) · Operating margin −0.5% · Revenue (TTM) 1.6B CNY · Revenue growth (YoY) −39.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).

What moves the price

The share trades about 45% below its 52-week high and 39% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 38% fair-value upside, at −74%, 0314 screens richer than that median.

Fair Value models

Bear HK$0.4335 Fair Value HK$0.4335 Bull HK$0.4420
Price HK$1.64 · Downside -73.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$0.5100 HK$0.5300 HK$0.5500 82
Growth DCF HK$0.5100 HK$0.5200 HK$0.5400 80
5Y Revenue Exit HK$0.5100 HK$0.5100 HK$0.5100 74
All 6 models by family
DCF Models
FCF DCF HK$0.5100 HK$0.5300 HK$0.5500 82
5Y Revenue Exit HK$0.5100 HK$0.5100 HK$0.5100 74
10Y Revenue Exit HK$0.5100 HK$0.5100 HK$0.5200 68
Multiples
EV/Revenue HK$0.4600 HK$0.4600 HK$0.4600 54
Asset-Based
NCAV (Graham) HK$0.6400 HK$0.9700 HK$1.21 55
Growth DCF
Growth DCF HK$0.5100 HK$0.5200 HK$0.5400 80

The fair value above starts from this blend and is adjusted for dilution from new shares.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 41/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 54
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 63
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 57
How calm the share price moves, does not count
Price momentum 43
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 13
Distance to the 52-week high, does not count
New shares 20
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 18/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−55.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−21.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−5.7%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+46.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−14.1% (2020) → −5.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

0314 screens overvalued: fair value 74% below the price. Compare with McKesson Corporation →

Compare Sipai Health Technology Co. Ltd. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Distribution · 81 stocks

Beats the industry median on 0/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 41 · Bottom 25%
Fair Value upside −73.5% · Bottom 25%
Profitability
Return on assets −7.6% · Bottom 25%
Net margin (12 months) −0.6% · Bottom 25%
Operating margin (12 months) −0.5% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −39.6% · Bottom 25%

Valuation Multiplesvs Medical Distribution median · lower = cheaper

P/B 1.08× · Pricier than median
P/S (12 months) 0.64× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 37
FUTURE (revenue growth)0 · sector 18
PAST (return on equity)0 · sector 25
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 54

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Distribution stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sinopharm Group 1099 HK$16.67 HK$50.01 +200% vs 0314
Jointown Pharmaceutical Group 600998 ¥5.09 ¥11.56 +127% vs 0314
Shanghai Pharmaceuticals Holding 601607 ¥16.13 ¥35.78 +122% vs 0314
China National Medicines Corporation 600511 ¥28.38 ¥58.47 +106% vs 0314
Guangzhou Baiyunshan Pharmaceutical Holdings 600332 ¥19.35 ¥26.64 +38% vs 0314
Cencora, Inc COR $359.03 $341.58 −5% vs 0314
Henry Schein, Inc HSIC $86.22 $78.69 −9% vs 0314
McKesson Corporation MCK $1,103 $822.74 −25% vs 0314
Galenica AG GALE CHF 91.20 CHF 61.79 −32% vs 0314
Cardinal Health, Inc CAH $281.10 $163.14 −42% vs 0314

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Average Down CalculatorFree calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sipai Health Technology Co. Ltd.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sipai Health Technology Co. Ltd. Fair Value". https://www.fairvalue-calculator.com/stock/0314

Frequently asked questions

Is Sipai Health Technology Co. Ltd. (0314) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$0.4335 versus a price of HK$1.64, about 74% lower (overvalued).
What is the fair value of 0314?
Our model-based fair value for Sipai Health Technology Co. Ltd. is HK$0.4335 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$1.64.
What is the quality score of 0314?
Sipai Health Technology Co. Ltd. has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sipai Health Technology Co. Ltd. (0314)?
Our model-based price target is the fair value of HK$0.4335 (as of Nov 14, 2026) from 6 valuation models. Cautious scenario HK$0.4335, optimistic scenario HK$0.4420. It is a calculation from audited fundamentals, not an analyst target.
What is the Sipai Health Technology Co. Ltd. stock forecast for 2026?
Our models put fair value at HK$0.4335, about 74% lower versus a price of HK$1.64 (overvalued). Cautious scenario HK$0.4335, optimistic scenario HK$0.4420. The calculation is refreshed regularly with new filings.
What is the revenue of Sipai Health Technology Co. Ltd. (0314)?
Sipai Health Technology Co. Ltd. reported trailing-twelve-month revenue of about 1.6B CNY (latest available figure, as of Nov 14, 2026).
What is the intrinsic value of Sipai Health Technology Co. Ltd. (0314)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sipai Health Technology Co. Ltd. it is HK$0.4335 per share (as of Nov 14, 2026), against a price of HK$1.64. It is the blended result of 6 valuation models in 4 families (DCF Models, Multiples, Asset-Based, Growth DCF).
Is Sipai Health Technology Co. Ltd. stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 0314 trades above its calculated fair value: price HK$1.64, fair value HK$0.4335, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0314?
No. The price is what the market pays today (HK$1.64); the fair value is what the company's own numbers justify (HK$0.4335). For Sipai Health Technology Co. Ltd. the two are HK$1.20 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sipai Health Technology Co. Ltd. worth?
The market values Sipai Health Technology Co. Ltd. at about HK$1.2B (market capitalisation, as of Nov 14, 2026). Per share that is HK$1.64; our models calculate a fair value of HK$0.4335 per share.
What do the bullish and bearish scenarios say about 0314?
Our models span a range for Sipai Health Technology Co. Ltd.: cautious scenario HK$0.4335, base HK$0.4335, optimistic HK$0.4420 per share (as of Nov 14, 2026, price HK$1.64). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sipai Health Technology Co. Ltd. (0314)?
Balance-sheet figures for Sipai Health Technology Co. Ltd. (as of Nov 14, 2026): return on equity −0.3%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 0314 from its 52-week high?
Sipai Health Technology Co. Ltd. trades at HK$1.64, about 45% below its 52-week high of HK$2.99 and 39% above the low of HK$1.18 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.4335 is for.
Which stocks are comparable to Sipai Health Technology Co. Ltd.?
From the same area (Healthcare) we also value McKesson Corporation, Cencora, Inc, Cardinal Health, Inc, Henry Schein, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sipai Health Technology Co. Ltd. stock attractive at the current price?
The data as of Nov 14, 2026: price HK$1.64, calculated fair value HK$0.4335 (−74%), Quality Score 41/100, from 6 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0314 calculated?
We run Sipai Health Technology Co. Ltd. through 6 models from 4 families: DCF Models, Multiples, Asset-Based, Growth DCF. Every model gets the same audited fundamentals; the fair value of HK$0.4335 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1% above its aggregate fair value. Sipai Health Technology Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sipai Health Technology Co. Ltd. (0314)?
The closing price on Nov 13, 2026 was HK$1.64. Our model-based fair value is HK$0.4335, about 74% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sipai Health Technology Co. Ltd. right now?
The price sits above even our optimistic bull case (HK$0.4420). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. The models converge in a tight band (HK$0.4335 to HK$0.4420), unusually little disagreement for a valuation.

Key figures of Sipai Health Technology Co. Ltd.

How large is the market capitalisation of Sipai Health Technology Co. Ltd. (0314)?
The market capitalisation of Sipai Health Technology Co. Ltd. is HK$1.2B (≈ $152M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sipai Health Technology Co. Ltd. (0314)?
The price-to-sales ratio of Sipai Health Technology Co. Ltd. is 0.62 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Sipai Health Technology Co. Ltd. (0314)?
The net margin of Sipai Health Technology Co. Ltd. is −0.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sipai Health Technology Co. Ltd. (0314)?
The return on equity (ROE) of Sipai Health Technology Co. Ltd. is −0.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sipai Health Technology Co. Ltd. (0314)?
On an EBIT basis the return on assets of Sipai Health Technology Co. Ltd. is −15.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sipai Health Technology Co. Ltd. (0314)?
The operating margin of Sipai Health Technology Co. Ltd. is −0.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sipai Health Technology Co. Ltd. (0314)?
Revenue at Sipai Health Technology Co. Ltd. is down 39.6% versus a year earlier (3y avg −21.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sipai Health Technology Co. Ltd. (0314) generate?
The free cash flow of Sipai Health Technology Co. Ltd. is 127K CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sipai Health Technology Co. Ltd. (0314) hold?
Sipai Health Technology Co. Ltd. holds more cash than debt, 284M CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sipai Health Technology Co. Ltd. in the live analysis

One click puts Sipai Health Technology Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.